{"original": "In relation to COVID-19, Friman et al. investigated the off-target effects of the broad-spectrum antiviral Remdesivir, one of the first drugs to be repurposed for use during the pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal shift assay, alongside the drug hydroxychloroquine, which has been subject to controversy. The study identified TRIP13 as a potential off-target for Remdesivir.\n\n\nIt ", "sampled": "</s>In relation to COVID-19, Friman et</s> addition. investigated the off-target effects</s> about the broad-spectrum antiviral Remdesivir, one of</s> those first drugs to be repurposed for use during</s> those pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal shift</s> verification, alongside the drug hydroxychloroquine, which has been subject to controversy. The study identified TRIP13 as a potential off-target for Remdesivir.\n\n\nIt ", "replacement_keys": [3, 12, 34, 20, 84, 69, 35, 46, 94], "original_crit": -1.2507908344268799, "sampled_crit": -1.7768172025680542, "original_llm_likelihood": 0.49, "sampled_llm_likelihood": 0.38}